Our Team
The SENVI team brings together a new generation of pioneering scientists and innovators who push boundaries and rethink what is possible in medicine. Our researchers combine rigorous science, bold curiosity, and cuttingedge technology with expert knowledge in cancer biology, senescence, and peptide engineering. Working within the state-of-the-art OHSU Knight Cancer Institute, Jared Fischer, PhD, and his team leverage world-class facilities and a highly collaborative environment to accelerate discovery. Supported by renowned industry leaders, we are building a culture where unconventional thinking, rapid iteration, and relentless problem-solving drive breakthrough discoveries. We are doing what’s never been done before.
Senescent cell accumulation is a key driver of aging, disrupting tissue function and promoting inflammation. Because aging is slow and not yet a defined regulatory indication, we are advancing our lead compound, SNC711, toward IND in oncology, where disease and treatment reproduce the hallmarks of aging in a rapid timeframe.

Steve Gorlin
CEO & Executive Chairman

Jose Trevejo MD, Ph.d
Board Member & Director of The Development Committee

Brian Druker, MD
Scientific Advisor & Board Member

Robert Langer, SCD
Board Member

Ed Miller, MD
Board Member

William Haseltine, Ph.d
Board Member and Chair of the Scientific Advisory Board

Michael Burns
Board Member

Jared Fischer. Ph.d
Chief Science Officer

Florian Gonclaves, Ph.d
Director of Senolytic Research

Bert O'Malley Jr., MD
Scientific Advisor

Lee A. Fleisher, MD, ML
Scientific Advisor